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The risk of premature mortality caused by cardiovascular diseases (CVDs) is
approximately three times higher in the Central Eastern European region than in high
income European countries, which suggests a lack and/or ineffectiveness of preventive
interventions against CVDs. The aim of the present study was to provide data on
the relationship between premature CVD mortality, statin utilization as a preventive
medication and socioeconomic deprivation at the district level in Hungary. As a
conceptually new approach, the prescription of statins, the prescription redemption
and the ratio between redemption and prescription rates were also investigated. The
number of prescriptions for statins and the number of redeemed statin prescriptions
were obtained from the National Health Insurance Fund Administration of Hungary for
each primary healthcare practice for the entire year of 2012. The data were aggregated
at the district level. To define the frequency of prescription and of redemption, the
denominator was the number of the 40+-year-old population adjusted by the rates of
60+-year-old population of the district. The standardized mortality rates, frequency of
statin prescriptions, redeemed statin prescriptions, and ratios for compliance in relation
to the national average were mapped using the “disease mapping” option, and their
association with deprivation (tertile of deprivation index as a district-based categorical
covariate) was defined using the risk analysis capabilities within the Rapid Inquiry Facility.
The risk analysis showed a significant positive association between deprivation and the
relative risk of premature cardiovascular mortality, and a reverse J-shaped association
between the relative frequency of statin prescriptions and deprivation. Districts with the
highest deprivation showed a low relative frequency of statin prescriptions; however,
significantly higher primary compliance (redemption) was observed in districts with the
highest deprivation. Our data clearly indicate that insufficient statin utilization is strongly
linked to the so-called physician-factor, i.e., a statin prescription. Consequently, statin
treatment is poor and represents a significant barrier to reducing mortality, particularly
among people living in highly deprived areas of the country.
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INTRODUCTION
The health status of the population of Central Eastern European
(CEE) member states of the European Union is less favorable
than that of the countries that became members before May 2004
(EU15 countries). Although the period of epidemiological crisis
plateaued between 1980 and the early 1990s in CEE countries
and although the mortality caused by cardiovascular diseases
(CVDs) is continuously decreasing, the relative risk of premature
death, i.e., the ratio between the death rates for CEE countries
compared with that of EU15 countries, is highly unfavorable. In
the Visegrad Group countries (Czech Republic, Hungary, Poland,
and Slovakia), the relative risk of early death caused by CVDs
varies between 1.96 and 3.18 (Czech Republic, 1.96; Poland,
2.57; Slovakia, 2.91, and Hungary, 3.18) according to the latest
available data (WHO HFA, 2015). These figures clearly indicate
that the effectiveness of preventive interventions against CVDs is
not sufficient in these countries; therefore, identifying gaps and
improving the scale and effectiveness of preventive interventions
are necessary in the region.
In addition to lifestyle modifying interventions, considerable
benefit can be derived from preventive medication, including
lipid-lowering therapy, particularly statin treatment (Perk et al.,
2012; Kypridemos et al., 2015). A meta-analysis of 10 randomized
trials enrolling a total of 70,388 people with a mean follow-up
of 4.1 years clearly showed that statin treatment significantly
reduced the risk of all-cause mortality (odds ratio 0.88), major
coronary events (0.70), and major cerebrovascular events (0.81).
In patients without established CVD but with cardiovascular
risk factors, statin use was associated with significantly improved
survival and large reductions in the risk of major cardiovascular
events (Brugts et al., 2009). It was clearly demonstrated that
every 1 mmol/l decrease in LDL cholesterol results in a 21%
decrease in cardiovascular events (Yusuf et al., 2009). Therefore,
statins are considered the first choice of drugs for patients with
hypercholesterolemia or combined hyperlipidemia to reduce
their risk of CVDs. Despite the presently growing number of
publications on certain adverse effects of statin medication,
it is considered to be obvious that the benefits of statins far
outweigh the risks for the vast majority of patients (Godlee,
2014).
Although epidemiological data clearly demonstrate that
cardiovascular mortality is much higher in CEE countries
(WHO HFA, 2015), no studies on the relationship between
statin utilization and socioeconomic characteristics of certain
population groups were performed in these countries thus
far. For the most developed countries, a large number
of studies were published on the effect of socioeconomic
status on statin utilization, with highly contradictory findings.
Studies from Australia, Sweden, Denmark and the US (Stocks
et al., 2004; Thomsen et al., 2005; Franks et al., 2010;
Ohlsson et al., 2010) suggest that statin prescription in these
countries has a socioeconomic gradient, typically among men,
with women having a lower prevalence of statin use with
increasing socioeconomic status. Furthermore, there is a less
than expected utilization among the more disadvantaged. In
a pharmacoepidemiological cohort study (Wallach-Kildemoes
et al., 2012) it was clearly demonstrated that the Danish
implementation of the high-risk strategy to prevent CVD by
initiating statin therapy is inequitable across socioeconomic
groups, reaching primarily high-risk individuals in groups
with lower risk socioeconomic position. However, independent
reports from the UK confirm that statin prescription is higher
in more deprived areas (Ashworth et al., 2007; Wu et al.,
2013). Similarly in New Zealand, those in the most deprived
socioeconomic areas were most likely to receive statins. At
ages of up to 75 years old, the use was higher among Maoris
than non-Maori, particularly in middle age range (in the 45–
54 age group, 11.6% of Maori received a statin prescription
compared with 8.7% of non-Maoris) (Norris et al., 2014). In
these studies, statin utilization was characterized by the frequency
of prescription for statins, but no data were published on
whether the patients redeemed their statin prescription (the
rate of primary non-compliance). However, previous studies
found that the overall adherence to treatment is low if statins
are used for primary prevention, such as for patients with
no previous cardiovascular events; with elevated cholesterol
levels, only half of those patients prescribed a statin takes
this medication on a regular basis (Mann et al., 2007). Long-
term adherence to preventive statin therapy was also found
to be decreased with decreasing income, especially in men
aged 40–64 years in Denmark (Wallach-Kildemoes et al.,
2013).
The aims of our present study were to provide data on statin
prescription and its relation to the socioeconomic characteristics
of various population groups in Hungary and, as a conceptually
new approach on the redemption and relationship between
redemption and prescription rates, to define the contribution
of patient and/or physician factors to the inefficiency of statin
utilization, if one exists, on CVD prevention. Because physicians
in general practice are the key persons that initiate, coordinate,
and provide long-term follow-up for CVD prevention (Mauskop
and Borden, 2011), our study was performed as a cross-sectional
analysis utilizing data on statin prescription and redemption
rates from all general practices in Hungary. Furthermore,
and the ratios of the statin prescription and redemption
rates were analyzed as functions of deprivation in the areas
served.
MATERIALS AND METHODS
This study focused on the comparative analysis of data for
prescriptions by general practitioners (GPs) and redeemed
prescriptions for statins in Hungary during 2012, the last year
for which all data necessary for the analysis were available in
validated databases in a district level study design. The ratios
between the number of redeemed prescriptions and that of the
prescriptions for statins were used to characterize the level of
primary non-compliance. The associations between deprivation
and premature mortality caused by diseases of the circulatory
system (ICD-10: I00-I99), particularly ischemic heart disease
(ICD-10: I25), as well as deprivation and statin utilization
(prescription, redemption, and ratio) were also assessed.
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FIGURE 1 | The spatial distribution of deprivation (A) and premature mortality due to diseases of the circulatory system (ICD-10.: I00-I99) (B) as well
as premature mortality due to chronic ischemic heart disease (ICD-10.: I25) (C) at the district level in Hungary, 2012.
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TABLE 1 | Mortality due to diseases of the circulatory system and chronic
ischemic heart disease at district level by DI tertiles, Hungary, 2012.
DI tertiles Mortality due to diseases
of the circulatory system
(ICD-10.: I00-I99)
Mortality due to chronic
ischemic heart disease
(ICD-10.: I25)
Relative risk (95% CI) Relative risk (95% CI)
I (Least deprived) 0.926 [0.914–0.938] 0.888 [0.870–0.906]
II 0.996 [0.984–1.009] 0.980 [0.961–1.000]
III (Most deprived) 1.137 [1.120–1.155] 1.233 [1.205–1.262]
Data
Administratively, Hungary is divided into 19 counties as well
as the capital Budapest; thus, it has 20 European regions at the
third level of the Nomenclature of Territorial Units for Statistics
(NUTS). The counties are further subdivided into 198 districts
constituting Local Administrative Units 1 (LAU1), formerly
known as NUTS level 4 of Hungary1.
For the year 2012, the mortality data were obtained from
the Hungarian Central Statistical Office, whereas population data
were obtained from the Central Office for Administrative and
Electronic Public Services. Both mortality and population data
for the districts were stratified by 5-year age bands and sex.
The number of prescriptions for statins and the number of
redeemed statin prescriptions were obtained from the National
Health Insurance Fund Administration of Hungary for each
primary healthcare practice for the entire year of 2012. According
to Hungarian regulations, GPs can prescribe only one type of
medicine as a 1-month dose for one prescription for people who
are taking long term medications. The data were aggregated at
the district level. To define the frequency of prescription and that
of redemption, the denominator was the size of the 40+-year-old
population that was adjusted for by the rate of the 60+-year-old
population of the district.
Deprivation Index (DI) Calculation
Deprivation index was used to provide information about socio-
economic deprivation at the district level compared with the
1http://ec.europa.eu/eurostat/ramon/statmanuals/files/KS-RA-07-005-EN.pdf
national average for 2011, the year of the last census in the
country. Socio-economic indicators for the DI were selected from
available data stored at the Regional Informational System of
the Ministry of Local Government and Regional Development.
The data were originally obtained from the Hungarian Central
Statistical Office (Census, 2011) and the Hungarian Tax and
Financial Control Administration (2011).
The method to calculate DI values was described previously
(Juhasz et al., 2010) and was successfully used in former studies
designed to characterize the association between deprivation and
mortality amenable to healthcare (Nagy et al., 2012) as well as
between deprivation and premature mortality due to alcoholic
liver disease (Nagy et al., 2014) in Hungary. Briefly, the DI is
based on seven elementary socio-economic indicators, including
income, level of education, rate of unemployment, rate of one-
parent families, rate of large families, density of housing and
car ownership. The variables were transformed using the natural
log transformation and standardization (z-scores). The district-
specific index is a weighted sum of the z-scores, with higher
values representing greater deprivation. The weight of each
variable was determined on the basis of the standardized scoring
coefficients using a principal component analysis. The areas with
positive index values are districts with a lower socio-economic
status compared with the national average, and the converse is
shown in districts with negative index values.
Study at the District Level
In Hungary, the number of GP practices operating in 1 781
municipalities was 6 658 in 2012. The size of the practices,
as the number of clients served, varied widely (800–3000
persons/practice), and the average size was 1488 persons/practice.
Generally, more family practices operate in higher populated
municipalities, whereas one family practitioner serves more than
one municipality in less populated areas. In addition, there are
primary healthcare practitioners with obligations to provide in-
area care and those without such obligations. Considering the
facts, that the free choice of family physician is a norm in
Hungary and the detailed population data for practices, as well
as the statin utilization data by age group are not available due
to personal privacy, and the DI is not available at the practice
FIGURE 2 | Relationship between the deprivation tertiles and the relative risk of premature mortalities caused by diseases of the circulatory system
(A) and chronic ischemic heart disease (B) for 2012 in Hungary.
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FIGURE 3 | The spatial distribution of the relative frequencies of statin prescription (A), redemption (B) and the relative redemption rate (relative
compliance) (C) at the district level in Hungary, 2012.
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level to reduce the risk of misclassification, we aggregated all
data to the district level. The deprivation for each district was
calculated using the population weighted average of DI. All
districts included in the analysis were classified into 3 groups
or tertiles, ranging from the least deprived (tertile I) to the
most deprived (tertile III), with each containing a third of the
population.
Using the “disease mapping” option within the Rapid Inquiry
Facility (RIF)(Beale et al., 2010), spatial patterns of cardiovascular
mortality (ICD-10: I00-I99) and mortality due to chronic
ischemic heart disease (ICD-10: I25) for the 40+ age group
for 2012 were investigated and visualized at the district level.
Indirectly, standardized mortality ratios were calculated using
sex- and age-specific death rates for the Hungarian population.
The frequency of prescriptions for statins, redeemed statin
prescriptions, and the ratios for compliance in relation to the
national average were also mapped using the RIF and their
association with deprivation was defined using tertiles of DI
as a district-based categorical covariate and the risk analysis
capabilities of the RIF. Chi-square tests for homogeneity and
linear trend were also performed to test the global association of
DI and mortality as well as statin utilization.
RESULTS
Association between Deprivation and
Premature Mortality Caused by CVDs
Deprivation index values defined by districts varied widely
from –3.76 to +5.83, which indicates a high level of socio-
economic inequalities in the country. The tertiles based on
the DI values were defined as ranges of –3.76 ≤ DI ≤ –0.6,
FIGURE 4 | Relationship between the deprivation tertiles and the relative frequencies of statin prescription (A), redemption (B) as well as the relative
redemption rate (C) for 2012 in Hungary.
TABLE 2 | Relative frequencies of prescription of statins, statin redeeming, and relative redeeming rates at district level by DI tertiles, Hungary, 2012.
DI tertiles Prescription of statins Statin redeeming Relative compliance
Relative frequency (95% CI) Relative frequency(95% CI) Relative redeeming rate (95% CI)
I (Least deprived) 1.001 [1.000–1.002] 0.985 [0.984–0.987] 0.984 [0.983–0.985]
II 1.014 [1.013–1.015] 1.001 [1.000–1.003] 0.988 [0.987–0.990]
III (Most deprived) 0.975 [0.974–0.976] 1.021 [1.020–1.023] 1.046 [1.045–1.048]
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with an average of –1.32 (tertile I); –0.6 < DI ≤ 0.58, with
an average of –0.04 (tertile II); and 0.58 < DI ≤ 5.83, with
an average of 1.59. The least-favored districts were found
in the northeastern and southwestern parts of Hungary in
2011, whereas the least deprived districts were located in
the northwestern part of the country and in the capital city
of Budapest and neighboring areas (Figure 1A). The spatial
distribution of premature mortality due to diseases of the
circulatory system (Figure 1B) and chronic ischemic heart
disease (Figure 1C) in Hungary was also characterized by
significant inequalities. The districts with the highest estimated
SMRs are localized in the more deprived areas, particularly for
chronic ischemic heart disease (Figures 1A–C; Table 1). This is
supported by the results of the risk analysis showing a significant
association between the relative risk of premature cardiovascular
mortality and deprivation (χ2 homogeneity = 405.15, P = 0,
χ2 linearity = 391.57, P = 0) as well as between deprivation and
premature mortality caused by chronic ischemic heart disease
(χ2 homogeneity = 443.89, P = 0, χ2 linearity = 412.96, P = 0)
(Figures 2A,B).
Statin Utilization (Prescription,
Redemption, and Their Ratios)
In Hungary, a total of 10 044 005 statin prescriptions
(simvastatin, atorvastatin, rosuvastatin, pravastatin, and
fluvastatin) were prescribed in 2012, and only 63.39 [63.37–
63.43] % (6 367 738) were redeemed. The frequency of
prescription was 1.971 [1.9701–1.9725] and the frequency of
redemption was 1.249 [1.248–1.251] per person aged 40+ years.
These values were considered the national average.
The frequency of statin prescriptions in relation to the
national average was higher in districts in the northwestern and
southeastern parts of Hungary and in the middle of the country
(Figure 3A). The districts with a higher relative frequency of
statin redemption were primarily located in the southern part
of Hungary (Figure 3B). Districts with a higher redemption
(primary compliance) rate were located along the axis in the
northeastern-to-southwestern direction of Hungary, although
the spatial distribution does not show clustering (Figure 3C).
The results of the risk analysis showed a reverse J-shaped
association between the relative frequency of statin prescriptions
and deprivation (Figure 4A). The areas of highest deprivation
showed a low relative frequency of statin prescriptions (1.89 per
person). A positive association was observed for the frequency
of statin redemption by degree of deprivation (Figure 4B).
Significantly higher compliance was observed in districts with
the highest deprivation (67.88% [67.812–67.951]) (Figure 4C;
Table 2).
DISCUSSION
Our present study was designed to answer the question
whether a lack and/or ineffectiveness of preventive medication
may also exist behind the about three times higher risk
of premature mortality caused by cardiovascular diseases in
the Central Eastern European region than in high income
European countries; hypothesising that preventive medication is
not adequately reaching people characterized by having higher
risk of CVD, especially in groups living in socioeconomically
deprived conditions. Analysing data on the relationship between
premature CVD mortality, statin utilization (the prescription
of statins, the prescription redemption and the ratio between
redemption and prescription rates) as a preventive medication
and socioeconomic deprivation at the district level in Hungary,
a significant positive association between deprivation and the
relative risk of premature cardiovascular mortality, and a
reverse J-shaped association between the relative frequency of
statin prescriptions and deprivation were found. In districts
with the highest deprivation a low relative frequency of
statin prescriptions was detected; however, significantly higher
primary compliance (redemption) was observed in these
districts.
The 2012 guidelines from the Fifth Joint Task Force of the
European Societies on CVD Prevention in Clinical Practice
recommend that all hypertensive patients with established CVD
or with type 2 diabetes and patients with an estimated 10-
year risk of cardiovascular death ≥5% based on the SCORE
chart should be considered for statin therapy (Stone et al.,
2014). The 2013 AHA/ACC (American College of Cardiology
Foundation/American Heart Association) guidelines on the
management of elevated blood cholesterol for the primary
and secondary prevention of atherosclerotic CVDs recommend
appropriate levels of statin therapy for different risk groups (high
intensity in patients with atherosclerotic CVD, moderate or high
intensity in patients with diabetes depending on their 10-year
risk of atherosclerotic CVD, and moderate or high intensity in
individuals aged 40 to 75 years without CVD or diabetes but with
a 10-year risk of clinical events >7.5% and an LDL-cholesterol
level of 1.8–4.9 mmol/l) (Yancy et al., 2013). The WHO guidelines
for the prevention of CVDs propose preventive medication to the
lower cholesterol level in all individuals with total cholesterol at
or above 8 mmol/l, but if the ten-year CVD risk is 20% or higher,
adults aged>40 years with a cholesterol level>5.0 mmol/l and/or
LDL cholesterol> 3.0 mmol/l despite a lipid-lowering diet should
be given a statin.
It is generally accepted, with minor limitations, that for
dyslipidemic persons who have not already had a vascular
event but are at a higher cardiovascular risk, combined statin
therapy substantially reduces the CVD mortality risk, thereby
“potentially being an ideal risk-reducing factor with added risk
reduction by lifestyle changes” (Opie, 2015). The evidence for
statins for secondary prevention in patients after a heart attack
is more robust, decreasing the risk of a second heart attack
by approximately one-third (Wei et al., 2005). Because in CEE
countries, including Hungary, the premature mortality caused by
CVDs is significantly higher than in the most developed countries
of the European Region, it is reasonable to suggest that preventive
interventions, such as preventive medication with statins, have
not been considered or implemented sufficiently.
Our results are consistent with findings published for
different countries (Mackenbach et al., 2000, 2003) and clearly
show that standardized mortality rates caused by CVDs,
particularly from chronic ischemic heart disease, are significantly
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higher in districts with the highest DIs (grouped into tertile
III) in Hungary. Although premature mortality caused by
CVDs, particularly by ischemic heart disease, is highest in
the same districts, the frequency of statin prescriptions at the
primary care level was significantly lower than the national
average. However, the rate of redemption, and consequently,
the ratio between redemption and prescription rates were
significantly higher. These data clearly indicate that insufficient
statin utilization is highly linked to the so-called physician-
factor; i.e., statin prescription, consequently statin treatment is
poor and represents significant barriers to mortality reductions,
particularly among people living in highly deprived areas of the
country. Because the socio-economic gap in health and mortality
is widening in Europe – as the largest study to have explored
the association between social factors and serious outcomes of
chronic diseases, particularly cardiovascular outcomes clearly
demonstrated (Mackenbach et al., 2003) – the identification
of gaps in preventive services in deprived areas is of the
utmost importance. The statement “reducing socio-economic
inequalities in mortality in Western Europe critically depends
upon speeding up mortality declines from CVDs in lower
socioeconomic groups, and countering mortality increases from
several other causes of death in lower socioeconomic groups”
can be interpreted as an imperative on how to improve the
health of the population for the low- and middle-income
countries of the European Region. Our study identifies a
gap in current cardiovascular prevention practice by showing
that many patients are likely under-treated and others remain
untreated.
Regarding the reasons and remedies for under-treatment, it
seems likely that the lack of financial incentives for primary
prevention at the level of primary care (Adany et al., 2013) has
a strong effect, particularly if it meets the low health literacy of
people living in the most deprived districts. Although a survey
(UNDP/World Bank/EC regional Roma survey 2011) revealed
a high percentage of households unable to afford prescription
medication in eleven countries of the CEE region, including
Hungary, our result showing significantly higher redemption
rates in the most deprived districts of the country indicates
that for statin prescription, the primary non-compliance, for
any reason, is not a factor highly defining the insufficient
preventive medication. Based on our results, the importance of
determining why GPs do not follow guideline recommendations
regarding lipid-lowering treatment should be emphasized.
Benefits provided by the National Health Insurance Fund of
Hungary include cost-free healthcare services, such as preventive
examinations, primary healthcare, and drug reimbursement
on grounds of equity. For persons who are low income or
on social welfare, medical exemption certificates are available,
such that they are exempt from prescription charges in the
case of defined medicaments, including the majority of statin
medicines.
The limitations of our study deserve mention. All three factors
(patient, physician, and health system) that have an effect on
statin utilization cannot be covered in a single study. The effects
associated with socio-economic factors may be mediated by other
factors that were not included in our analyses. Health system
factors were only partially studied, and access to care requires
particular attention in further studies. Information about various
elements that may influence a patient’s likelihood to take statin
medications should also be collected to understand the relatively
low redemption rate in areas with the lowest deprivation indices.
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